Soluble klotho and mortality: the Ludwigshafen Risk and Cardiovascular Health Study
Background: Experimental evidence suggests that soluble klotho (s-klotho), a co-receptor for fibroblast growth factor 23 (FGF23), may modulate cardiovascular risk through multiple mechanisms. However, the predictive value of s-klotho in patients remains unclear. Therefore, the present study examined...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 2015
|
| In: |
Atherosclerosis
Year: 2015, Jahrgang: 242, Heft: 2, Pages: 483-489 |
| ISSN: | 1879-1484 |
| DOI: | 10.1016/j.atherosclerosis.2015.08.017 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.atherosclerosis.2015.08.017 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0021915015300800 
|
| Verfasserangaben: | Vincent M. Brandenburg, Marcus E. Kleber, Marc G. Vervloet, Tobias E. Larsson, Andreas Tomaschitz, Stefan Pilz, Tatjana Stojakovic, Graciela Delgado, Tanja B. Grammer, Nikolaus Marx, Winfried März, Hubert Scharnagl |
| Zusammenfassung: | Background: Experimental evidence suggests that soluble klotho (s-klotho), a co-receptor for fibroblast growth factor 23 (FGF23), may modulate cardiovascular risk through multiple mechanisms. However, the predictive value of s-klotho in patients remains unclear. Therefore, the present study examined in a large cohort of patients referred for coronary angiography whether s-klotho is associated with cardiovascular and total mortality. Methods: The longitudinal associations between baseline s-klotho and FGF23 concentrations and mortality were evaluated in 2948 participants of the Ludwigshafen Risk and Cardiovascular Health Study (LURIC), referred for coronary angiography. Results: Mean age of participants was: 63 ± 10 years. Patients with diabetes mellitus (n = 1136) had elevated s-klotho: [440 (430-449) versus 414 (406-421) pg/mL, p < 0.001]. S-klotho decreased in parallel to glomerular filtration rate (GFR) and increased in parallel to FGF23. During a median follow-up of 9.9 years, 874 deaths (30%) occurred, 539 (18%) of which were cardiovascular. After adjustment for cardiovascular risk factors, the hazard ratios in the fourth quartile compared to the first quartile of s-klotho were 1.14 (95%CI, 0.94-1.38; p = 0.187) for all-cause mortality and 1.03 (95%CI, 0.80-1.31; p = 0.845) for cardiovascular mortality. Excess mortality prediction by high levels of baseline FGF23 was not modified by adjustment for baseline s-klotho levels. Conclusions: Klotho does not add predictive power to cardiovascular and mortality risk assessment in patients with normal renal function. |
|---|---|
| Beschreibung: | Gesehen am 25.01.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1879-1484 |
| DOI: | 10.1016/j.atherosclerosis.2015.08.017 |